U.S. Markets closed

NextGen Healthcare (NXGN) Q1 2020 Earnings Call Transcript

Motley Fool Transcribers, The Motley Fool
Logo of jester cap with thought bubble.

Image source: The Motley Fool.

NextGen Healthcare  (NASDAQ: NXGN)
Q1 2020 Earnings Call
Jul. 24, 2019, 5:00 p.m. ET

Contents:

  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Operator

Welcome to the NextGen Healthcare Fiscal 2020 First Quarter Results Conference Call. Hosting the call today from NextGen are Rusty Frantz, President and Chief Executive Officer; and Jamie Arnold, Chief Financial Officer.

[Operator Instructions]

Before we start, I would like to remind everyone that the comments made on this call may include statements that are forward-looking within the meaning of the federal securities laws, including and without limitations, statements relating to anticipated industry trends, the Company's plans, future performance, products and perspectives and strategies. Risks and uncertainties exist that may cause results to differ materially from those expressed in these forward-looking statements, including among others, those risks set forth in the Company's public filings with the US Securities and Exchange Commission, including the discussion under the heading Risk Factors in the Company's most recent Annual Report on Form 10-K and any subsequent quarterly reports on Form 10-Q. Any forward-looking statements speak only as of today. The Company expressly disclaims any intent or obligation to update these forward-looking statements.

Our remarks on today's call include both our earnings results and guidance, which contains certain non-GAAP financial measures. For our earnings results, the GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measures can be found within our latest quarterly earnings press release that was filed with the SEC and is posted to the Investors section of our website. This release also provides qualitative descriptions of how we have calculated non-GAAP financial measures contained in our guidance.

At this time, I would like to turn the call over to Mr. Rusty Frantz, President and CEO of NextGen. Sir, you may begin.

Rusty Frantz -- President and Chief Executive Officer

Thank you, operator and thank you to everyone for joining us this afternoon to review NextGen Healthcare's fiscal first quarter of FY '20. However, before I do, I would like to welcome Jamie Arnold back to the earnings call.

As I said on the last call, Jamie had been hospitalized and discharged to a rehab facility. From what was a scary moment for all of us only eight weeks ago to now, I can only say that I am so grateful, both personally and professionally to have Jamie back at full speed.

Turning now to NextGen, in Q1, our revenue came in at $131.9 million compared to $133.2 million a year ago, and our non-GAAP of $0.016 compared to $0.19. Bookings for the quarter came in nicely at $31.7 million versus $29.1 million in the same-quarter last year. Operating cash flow for the quarter was $17 million and NextGen generated $9 million in free cash flow, as our cash generation capabilities continue to expand our storehouse of dry powder. While we're excited to see a 9% year-over-year uplift on bookings performance in line with our expectations, we are seeing our recognizable perpetual bookings becoming a smaller than expected percentage of the overall bookings, which is having an impact on full-year revenue. Additionally, on the revenue line, one of our larger client bookings from last year has run into challenges. As we moved into this year, we expected to see that turn into recurring revenue. Unfortunately, the client has had significant operational and financial troubles and we no longer expect to see revenue from this client, putting further pressure on our FY '20 full-year top line. Jamie will dive deeper into the impacts in a few minutes.

As for EPS, our $0.16 came in line with our expectations and should increase nicely through the year, as the benefit of both revenue growth and our focus on efficiency enable increased earnings production. Legacy maintenance retention came in at 89% over the trailing 12 months or right there at FY '20 modeled level. As we stated on the last call, we anticipate some volatility in the retention rate as we move forward and believe our modeled level as appropriate.

As we look at Q1 deal flow, 14 clients entered into arrangements over $500,000 in the quarter. These larger deals continue to show how our broader platform and all-in deal approach are driving increased deal sizes and how our cross-sell capabilities continue to support our bookings growth.

As we look into the accomplishments since the last earnings call, a number of key achievements and events stand out. From a client satisfaction standpoint, we are very gratified to once again be recognized by KLAS. In February, we were awarded Best in KLAS for project management for 11 to 75 providers. Just recently, KLAS updated their analysis announcing that NextGen now has the top scores across all ambulatory organizations greater than 11 providers. In fact, 50% of our large practice clients with greater than 75 providers reporting high satisfaction, the most among all measured vendors. We are very proud of this accomplishment, but are by no means resting on our laurels.

In addition, we recently received the results of our internal voice of client scores for our Enterprise Financial Services Solutions, which primarily include our revenue cycle management business. We've completely reinvented and replatformed this part of NextGen, a path that has great benefit, as well as some risk during the transition. As we emerge from this significant change, we are very proud to see amazingly positive feedback from our clients. Our net promoter score for NextGen Enterprise Financial Services rose 33 points from a year ago, up to 46.3. In fact, 90% of our clients responded that they are likely to recommend our services. Great to see the progress and the resulting client satisfaction increases.

In June, we had our large client user group. We get together with 100 to 150 of our largest clients twice a year to discuss market dynamics, our strategic response and to get feedback on how we are performing for them. It was great to get both a good bit of positive feedback, but also to identify some key needs that span our clients and discuss some areas where we can continue to improve. Every user group through my tenure has been better and more beneficial than the one before, and this one was no exception.

Turning to our expanding capabilities, I'd like to discuss a few recent introductions. In April, we released the Spring 2019 release of our NextGen Enterprise platform. With this release, our clients have seen another step forward in usability, scalability and performance. Client feedback has been very positive and we are starting to see some meaningful uptick on the release.

In addition, in late May, we announced the release of our Behavioral Health Suite 3.0, a major step forward as we look to be a strong part of enabling behavioral health to be a key part of improving both mental and full body health in our country. We see opportunity in this increasingly important and growing part of our healthcare ecosystem and look forward to further building out both innovation and commercial capabilities for this market.

Our population health analytics suite continues to see success in the market, both within our client base but also in new to NextGen footprint. In fact, in the quarter, we were proud to close another critical care hospital, further illustrating the broad value that our solution can provide, not only in the ambulatory segment but in others. We look forward to further success and increasingly broad capabilities as we continue to focus on enabling our clients to perform well in both fee-for-service and risk-based arrangements.

We're also starting to see success with our optimization services. As clients become much more comfortable with NextGen as a long-term partner, they are moving from a potential replacement to desired optimization. We've signed a number of value-added service engagements to come in and work with the clients to ensure that their clinical, financial and operational processes are hitting on all cylinders. More to come as this capability continues to evolve and expand and begins to show up on the non-recurring service line.

Last quarter, we discussed a couple of areas where we are evolving our structure, investing in some areas and pulling back in others. Most notably, we've chosen to expand our footprint in our Bangalore development center. We are a ways through that pivot and can report that it is going very well. We have nearly fully staffed our teams there and already gaining great momentum.

In addition, we recently received the Zinnov Awards 2019 Jury Special Mention Award for our exceptional work in a relatively short span in India. The Zinnov Awards are very important in the Indian market and it was amazing to be recognized along some very large, long-tenured companies in the Indian market, such as PayPal, Dell, Samsung and MasterCard. This recognition increases the attractiveness of us as an employer in the market, but also validates the great work both the team has done there and the great work that our broader team has done for our clients. However, with this expansion in Bangalore, we've also pulled back in select markets across the US. To that end, we've established a restructuring bucket as we ensure anyone leaving the organization has a smooth transition and a soft landing.

Now let me turn to Jamie for a dive into the numbers. Jamie?

James Arnold -- Chief Financial Officer

Thank you, Rusty. And thank you to everyone on the call. Before I provide commentary on the numbers, I want to thank all of you who sent notes and well wishes while I was ill. During my stay in the hospitals and subsequent recovery at home, the notes brightened my spirits and provided much needed positive energy. Over the last eight weeks, I've learned a lot about healthcare and healthcare IT. I feel fortunate to be almost fully recovered from a very scary situation and I'm excited to be back and part of the NextGen team. Again, thank you for your support.

As Paul Harvey used to say, and now for the rest of the story. Total revenue of $132 million declined 1% compared to the same period last year and was largely in line with our expectations. Recurring revenue of $119.4 was essentially flat compared to a year ago with a decline in maintenance and managed services, largely offset by an increase in subscription service. Recurring revenue is 91% of our total revenue, slightly higher than the 90% in the same quarter of the prior year. Subscription revenue of $30.1 million increased 6% compared to a year ago. The growth was primarily driven by our patient portal, NGE, SaaS and analytic solutions. Support and maintenance revenue of $39.7 million, decreased 4% year-over-year due to attrition in our legacy NGE customers partially offset by new contracts and CPI increases.

Managed services revenue of $25.7 million decreased 2% compared to a year ago due to attrition within the RCM customer base, as noted on previous calls, almost entirely offset by new contracts. And while we work through the challenge Rusty referenced in his comments, we remain focused on driving RCM penetration in our customer base, as well as leading within in proposals to new customers.

EDI and data services revenue of $24 million was essentially flat year-over-year, with a decline in third-party data revenue, largely offset by increased in EDI to clients. Note, we are down relative to the prior quarter Q4 of FY '19, as last quarter, we had a one-time benefit from the signing of the Veradigm contract; non-recurring or one-time revenue of $12.4 million, a 6% reduction over the same quarter last year. Software license and hardware revenue of $7.1 million declined 5% year-over-year. And as Rusty noted, we've seen a measurable trend away from licenses and toward subscription. Non-recurring service revenue of $5.3 million decreased 7% compared to a year ago, due to lower legacy consulting engagements offset by analytics-related services.

Bookings came in at $31.7 million in the quarter, up 9% on a year-over-year basis. Cost of goods increased due to higher amortization of capitalized development costs and the direct charging of hosting to cost of goods sold and transfer of personnel from operating expenses to cost of goods.

Gross profit declined 7% to $66.6 million and gross margin declined to 50.5% compared to the prior-year quarter of 53.6% and this is due to the decrease in COGS just discussed above, along with modest decline in revenue.

Taking a look at our operating expenses, SG&A of $40.1 million is 10% reduction from $44.6 million a year ago. The decrease is primarily due to lower acquisition related costs and the transfer of cost to COGS mentioned above, as well as other lower costs due to cost savings initiatives. R&D of $22.1 million was flat compared to a year ago. The restructuring charge of $1.7 million is related to cost associated with the reduction of approximately 4% of our workforce, primarily within research and development, as we transition to more resources in India. As part of the restructuring, we also downsized several facilities, which resulted in the $500,000 impairment charge.

Our GAAP tax rate for Q1 fiscal '20 was a benefit of 43.9% with a non-GAAP tax rate of 22%. The GAAP tax benefit for Q1 is the result of federal IRS audit adjustments and excess tax benefits related to stock compensation. For fiscal year '20, we will continue to use a non-GAAP tax rate of 22%.

To conclude my comments on the income statement, our Q1 GAAP EPS of $0.02 compared to $0.04 a year ago; our non-GAAP EPS of $0.16 for Q1 decreased by $0.03 year-over-year.

Turning to the balance sheet, we ended the quarter with $28.6 million in cash and equivalents, and $6 million outstanding against our revolving credit agreement. We paid down $5 million against the revolving credit agreement in the quarter just ended. DSOs in the quarter were 57 days, a decrease of 2 days from last year and last quarter, all within our expected range of 55 days to 60 days. Our capex excluding capitalized R&D was $3.8 million; capitalized R&D was $4.7 million.

To close the call, I will update our initial outlook for fiscal 2020. We expect revenue to be between $536 million and $550 million. Previously, we had expected revenue to be between $543 million to $559 million. This reflects the headwinds we are facing in the managed services and software areas. Non-GAAP is now expected to be between $0.82 to $0.90 per share. This was previously $0.86 to $0.94 per share. Note that we see the year backloaded in terms of growth as we are only starting to see the benefits of current client and corporate projects. Overall, I am generally pleased with our performance in Q1, as we execute on our strategic plan and I'm looking forward to continued progress in fiscal '20.

This concludes my review of the first quarter financial results. I will turn the call back to Rusty.

Rusty Frantz -- President and Chief Executive Officer

Thank you, Jamie. In summary, while we we're not pleased with the impacts to full year revenue and the resulting impacts for earnings, we are gratified with the great progress the organization is making, our continued solid bookings performance and the continuous improvements to client satisfaction and organizational capabilities we're delivering. We have confidence in our ability to execute and look forward to continued progress throughout the year toward our goal of mid to high single digit revenue growth in FY '21, leading to significant operating leverage in FY '22.

In closing, I wanted to express my gratitude to the amazing clinical folks across our client base and our nation. I wake up every day thankful for the commitment to great outcomes that have brought the most important person in my life back from the edge on multiple occasions, and now we have our friend and teammate, Jamie, back in in good health following a scary time. We at NextGen have the honor to work tirelessly to support these amazing caregivers, all the while making healthcare better, more accessible, more affordable and more rewarding to practice. It's an effort that we know can enable the great outcomes that keep our friends and family healthy, happy and productive. We are a business that constantly strives to do well, but more importantly are gratified that doing well comes from doing good.

Thank you. And I'll now open it up to questions.

Questions and Answers:

Operator

[Operator Instructions] And your first question comes from the line of Ricky Goldwasser with Morgan Stanley. Please go ahead.

Alexa Desai -- Morgan Stanley -- Analyst

Hi, this is actually Alexa in for Ricky, can you hear me OK?

Rusty Frantz -- President and Chief Executive Officer

Yep.

Alexa Desai -- Morgan Stanley -- Analyst

Great. So I just -- I kind of wanted to unpack your comments on the larger client booking loss from last year. So you said they went into operational challenges. So can you maybe give a little bit more color on what they -- what was happening with them, when they notified you about these issues and...

Rusty Frantz -- President and Chief Executive Officer

My apologies, that is confidential and proprietary for the clients. What I would say is that, it was not a NextGen issue that caused this to go in this direction. And so we had a significant booking -- the booking was give or take about $4 million annually, and we had reason to expect that they were going to solve their financial problems as we came into this year and just in the last month or so, we've realized that that is -- we have come to the conclusion that that is not going to happen. Now, fortunately, because we are conservative, we did not actually book revenue on this. And so as they came to this point, we are simply removing it from our revenue forecast and moving on.

Alexa Desai -- Morgan Stanley -- Analyst

Got it. Okay. And I guess just to follow up on that, do you -- in terms of your other clients and that the bookings that you made last year, do you foresee this issue coming up with anybody else or are you fairly confident in the rest of the revenue forecasts for the year?

Rusty Frantz -- President and Chief Executive Officer

Yeah. The only reason we actually bring this forward is two-fold. Number one, it's material to the forecast this year, and number two, it's an extraordinary event for us to have something go this way. And therefore, we felt like in the interest of transparency that we needed to share with the investment community the fact that one of the two very large bookings for last year was not turning into revenue and therefore impairing this year's revenue forecast.

Alexa Desai -- Morgan Stanley -- Analyst

Got it. Okay, and then just a second one for me. On the retention, you said 89%, which is exactly the amount you guys are modeling for the full year, so that's great. Just in terms of how you're thinking about it for the rest of the year, you guys have previously mentioned, the key factor to watch is just hospitals and systems migrating toward single stack. And so do you guys foresee any of that happening later to the year or you -- is everything kind of just stable as of now?

Rusty Frantz -- President and Chief Executive Officer

Look, I mean, I think we've been pretty clear in the past that a lot of our exposure to hospital consolidation has already run off. And so attrition is just a difficult thing to forecast. We -- that's why we say the number is somewhat volatile, because frankly, you can only read so much into the minds of your clients. But as we've talked about before, we've put a robust, proactive process to stabilize the client base. And because of that, we feel like we've done a good job of managing and retaining our clients. But as I said, it is a volatile number.

Alexa Desai -- Morgan Stanley -- Analyst

Okay. Thanks.

Rusty Frantz -- President and Chief Executive Officer

Thank you.

Operator

And your next question comes from the line of Sean Wieland with Piper Jaffray. Caller, please go ahead.

Sean Wieland -- Piper Jaffray -- Analyst

Ah, close enough, it's Sean Wieland from Piper. Hey, thanks. So, what's going on with the transfer of expenses from opex to COGS, particularly in sales and marketing?

James Arnold -- Chief Financial Officer

It's really G&A, Sean. We moved some people from who historically had been part of our IT organization into -- because the vast overtime they'd been doing more work is related to supporting clients, particularly in the managed services area. And so we made the decision that it should be -- that they should be properly classified as cost of goods.

Rusty Frantz -- President and Chief Executive Officer

Yeah, they're supporting ongoing revenue generation.

James Arnold -- Chief Financial Officer

So it is just one of those things that legacy we started using them and then as we look at it organizationally, we actually I think made this move middle of last year, but it didn't really show up in the cost of goods. And as I was reviewing the variance for this quarter and I figured it was worth calling out, since G&A went down, cost of goods went up, it's easy to explain it. Does that make sense?

Sean Wieland -- Piper Jaffray -- Analyst

Yeah, I think so. Can you maybe quantify what the point of impact is on the margin or number of people?

James Arnold -- Chief Financial Officer

Round numbers, it's about $2 million this quarter. I think about $1.5 million to $2 million. I'm doing it off the top of my head. but I believe that's pretty accurate.

Sean Wieland -- Piper Jaffray -- Analyst

And then so, other than the $4 million annualized hit from that deferral of the bookings, what else is going on with the revenue to cause the guide down?

Rusty Frantz -- President and Chief Executive Officer

Well, what we're seeing, Sean, is we are seeing clients -- and we think this is also a function of the financial pressure on the client base. We are seeing clients move more and more toward recurring and subscription models. And so, we had over the last two years, we've been relatively -- FY '18 and '19, we were relatively stable from a soft, perpetual -- instantly recognizable, perpetual license standpoint. As we both got in through this quarter and then started to look at the full year forecast, we do feel like it's taking another step down. And so unfortunately, as perpetual license revenue turns into subscription revenue, it's great for the long term, but it does create a temporal problem within the ear. And so as quickly as we started to see this dynamic emerge and take another step down, we had to build that into our forecast.

Sean Wieland -- Piper Jaffray -- Analyst

Okay. And then one more quick one. You have any update on the 20% operating margin goal for FY '22?

Rusty Frantz -- President and Chief Executive Officer

Yes. As I said in the opening call, if you'll notice, I said significant operating leverage, I did not say 20%. Our view and we are more still -- frankly, Sean, we're still updating our model based on kind of this new reality. Our view is this probably pushes the 20% into FY '23.

Sean Wieland -- Piper Jaffray -- Analyst

Okay. Thank you.

Rusty Frantz -- President and Chief Executive Officer

Thank you.

Operator

And your next question comes from the line of Mike Ott with Oppenheimer. Please go ahead.

Mike Ott -- Oppenheimer -- Analyst

Good afternoon. Thanks for taking my question. Curious if it's possible to allocate the rev guidance reduction between the lower perpetual bookings mix and then the customer that had the challenges. If you can break that out?

Rusty Frantz -- President and Chief Executive Officer

Well, it was a $4 million client and we lowered by $8 million [Phonetic].

Mike Ott -- Oppenheimer -- Analyst

Okay, that makes it easy. Okay.

Rusty Frantz -- President and Chief Executive Officer

Even for the CEO, that's the math I can do.

Mike Ott -- Oppenheimer -- Analyst

Okay. And then sticking with --

James Arnold -- Chief Financial Officer

[Speech Overlap] the next time you see him.

Mike Ott -- Oppenheimer -- Analyst

Great. And then sticking with the bookings last quarter, I recall they were $4 million to $5 million behind your internal expectations. Curious if any of that benefited the quarter you just reported [Indecipherable].

Rusty Frantz -- President and Chief Executive Officer

No, I mean as I said on the last call, I said, look, every single quarter I have my sales team tell me that something slipped. If something slips every quarter, it's not slipping. So last quarter we delivered below our expectations. This quarter we delivered on our expectations. And frankly, most of that was more of the organic things we expected to happen in this quarter. Maybe on the margins, some things slip from Q4 to Q1, but as I said, you can say that about pretty much every quarter.

Mike Ott -- Oppenheimer -- Analyst

All right. Fair enough. Thanks, guys.

Operator

And your next question comes from the line of Stephanie Demko with Citi. Please go ahead.

Stephanie Demko -- Citi -- Analyst

Hey, guys. Thank you for taking my question. I just want to get a quick update on Veradigm and the strategy you're seeing there, is there any early traction and if you're looking at other ways to monetize that data opportunity to kind of help your topline?

Rusty Frantz -- President and Chief Executive Officer

Yes. I think, look, the Veradigm piece, as Jamie said, we had a small one-time revenue event in Q4 that represented kind of the instantiation of the agreement. We expect revenue to start flowing from the Veradigm relationship in the back half of the year. And so at this point in time, we're still in the process of onboarding onto the Veradigm consortium. And as we move through toward the back end of the year, we'll update you there.

From the standpoint of additional data monetization opportunities, I'd say right now we're focused -- we're kind of sticking to our knitting. We've joined the Veradigm consortium, we're very focused on making that effective. And then on the other side, we're very focused more on the operational play of supporting our clients business rather than finding additional ways at this point to drive value from the identified data.

Stephanie Demko -- Citi -- Analyst

All right, thank you so much. And can we talk a little bit about how that affects kind of the margin side of things as we look at margin expansion out years?

Rusty Frantz -- President and Chief Executive Officer

I'm sorry, you broke up a little bit, so can you repeat that Stephanie.

Stephanie Demko -- Citi -- Analyst

Sorry about that. I was just wondering if we could -- if there's any sort of margin contribution we can think of and how that can impact out your margin expansion target?

Rusty Frantz -- President and Chief Executive Officer

This is specific to Veradigm?

Stephanie Demko -- Citi -- Analyst

Specific to Veradigm, the revenues stream, how we should think about that, the incremental --

Rusty Frantz -- President and Chief Executive Officer

I would think about that as being a revenue contributor, but I would be much more focused on the rest of the P&L, right. As we sit here today, we see Veradigm a little more on the margins. It's a nice additive, but it's not, by no means, the core focus and the core value driver in the P&L. And so we think -- look, it may have a slight positive, but it's a complex P&L; there's positives, there's negatives. I think it's more that we feel like when it comes out in the wash, it is revenue growth and efficiencies on the broad P&L that are going to get us to the margin target.

Stephanie Demko -- Citi -- Analyst

I understood. Thank you for taking my questions.

Rusty Frantz -- President and Chief Executive Officer

Thanks, Stephanie.

Operator

[Operator Instructions] And we have a question from the line of Gene Mannheimer with Dougherty & Company. Please go ahead.

Gene Mannheimer -- Dougherty & Company -- Analyst

Thanks. Good afternoon. And first of all, good to have you back in the saddle, Jamie.

James Arnold -- Chief Financial Officer

Thank you, Gene.

Gene Mannheimer -- Dougherty & Company -- Analyst

You're welcome. My question just going back to the trend in bookings toward more subscription and longer-term recognition. I mean, if we just say the $32 million or so in bookings that you did this quarter, how much of that say would convert to revenue in the current year versus historically?

Rusty Frantz -- President and Chief Executive Officer

I would say that the vast majority of it converts within the current year, especially given that it's Q1. But, we haven't really unpacked kind of time for bookings, as much to say that the vast majority of our bookings do go turn to revenue within a year.

In fact, I mean, the reason both the materiality to the forecast of this one transaction, but also because frankly, we do have such good conversion that the loss of this one deal -- it was actually a relatively extraordinary event, which is why we talked about it on the call, because frankly, what it means is, there is $4 million out of the give or take $130 million that we delivered last year that we now expect to not turn into revenue. That's a somewhat extraordinary event for us and one that because of that, we elevated to the level of an earnings call.

Gene Mannheimer -- Dougherty & Company -- Analyst

Okay. That's very helpful. Thanks.

Okay. That's very helpful. Thanks. And with respect to the restructuring and the shift of R&D resources to Bangalore, I mean, I would think that would be a benefit to you on the EPS line. Maybe you could quantify that for us, Jamie, because, certainly you're reducing the EPS guidance I understand why, but how much of a benefit would this R&D restructuring deliver?

Rusty Frantz -- President and Chief Executive Officer

Gene, I'm actually going to answer that qualitatively. R&D restructuring was not driven by cost reductions. The R&D restructuring was driven by increased regulatory intensity from the government, as well as continuing increasing needs from the client base. When it came down to it, our capacity model was not enough with the ramping up of government regulation to be able to both deliver the capabilities our clients need to win and also deliver the capabilities that the government requires them to. And so based on that, we actually needed to expand our capabilities and expand our headcount. And so we are -- this enabled us to do that cost neutrally, but does not create EPS favorability. It creates future optionality from an innovation standpoint.

Gene Mannheimer -- Dougherty & Company -- Analyst

All right. Very good. Thank you.

Rusty Frantz -- President and Chief Executive Officer

Thank you.

Operator

And we have no further questions at this time.

Rusty Frantz -- President and Chief Executive Officer

All right. Well, I'm going to thank Cerner for taking all the rest of the questions away since their earnings call just started. But thanks, everybody for hanging in there. We will look forward speaking to everybody on the next call. Thank you.

Operator

[Operator Closing Remarks]

Duration: 33 minutes

Call participants:

Rusty Frantz -- President and Chief Executive Officer

James Arnold -- Chief Financial Officer

Alexa Desai -- Morgan Stanley -- Analyst

Sean Wieland -- Piper Jaffray -- Analyst

Mike Ott -- Oppenheimer -- Analyst

Stephanie Demko -- Citi -- Analyst

Gene Mannheimer -- Dougherty & Company -- Analyst

More NXGN analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.


Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

This article was originally published on Fool.com